In latest setback, AstraZeneca’s high hopes for its lupus drug anifrolumab crushed by a PhIII failure
The last of the late-stage autoimmune drugs still left at AstraZeneca just went down to a stinging defeat in Phase III.
The pharma giant didn …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
